Seattle Biotech OncoResponse Raises $40.6M to Create Antibody-Based Treatments for Cancer

OncoResponse, a Seattle biotech company focused on developing antibodies to make immunotherapy treatments, announced a $40.6M Series C investment round. The additional founding, led by members of the Magnetar Group, is aimed to help the company continue to create cancer fighting antibodies.

To date, OncoResponse, which is led by CEO and founder, Clifford Stocks, has raised nearly $110 million.